BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang TY, Liao JN, Chao TF, Vicera JJ, Lin CY, Tuan TC, Lin YJ, Chang SL, Lo LW, Hu YF, Chung FP, Chen SA. Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios. Int J Cardiol Heart Vasc 2018;20:56-62. [PMID: 30186937 DOI: 10.1016/j.ijcha.2018.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Chan YH, Lee HF, Li PR, Liu JR, Chao TF, Wu LS, Chang SH, Yeh YH, Kuo CT, See LC, Lip GYH. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. Cardiovasc Diabetol 2020;19:63. [PMID: 32404168 DOI: 10.1186/s12933-020-01043-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
2 Linz D, Ammirati E, Dan GA, Heijman J, Dobrev D. Highlights from the International Journal of Cardiology Heart & Vasculature: Heart failure, atrial fibrillation, coronary artery disease and myocardial infarction. Int J Cardiol Heart Vasc 2019;25:100443. [PMID: 31890863 DOI: 10.1016/j.ijcha.2019.100443] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Linz D, Dobrev D. Outcome of atrial fibrillation ablation in pulmonary hypertension: Is pulmonary hypertension a modifiable risk factor? Int J Cardiol Heart Vasc 2019;23:100360. [PMID: 31016225 DOI: 10.1016/j.ijcha.2019.100360] [Reference Citation Analysis]
4 Gawałko M, Dobrev D. Surgery-related cardiac stress: A susceptibility test of late atrial fibrillation recurrence? Int J Cardiol Heart Vasc 2021;32:100693. [PMID: 33426267 DOI: 10.1016/j.ijcha.2020.100693] [Reference Citation Analysis]
5 Heijman J, Dobrev D. Bayesian network analyses in atrial fibrillation - A path to better therapies? Int J Cardiol Heart Vasc 2019;22:210-1. [PMID: 30963097 DOI: 10.1016/j.ijcha.2019.02.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Gawałko M, Elliott A, Kadhim K, Sanders P, Linz D. A call for a more objective and longitudinal reporting of lifestyle components in cardiovascular research. Int J Cardiol Heart Vasc 2020;27:100506. [PMID: 32310240 DOI: 10.1016/j.ijcha.2020.100506] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Tchen S, Ryba N, Patel V, Cavanaugh J, Sullivan JB. Validation of Bleeding Risk Prediction Scores for Patients With Major Bleeding on Direct Oral Anticoagulants. Ann Pharmacother 2020;54:1175-84. [DOI: 10.1177/1060028020933186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 den Uijl DW, Crijns HJGM, Vernooy K, Linz D. Hypnotic communication during atrial fibrillation ablation: Another clinical application of hypnotherapy? Int J Cardiol Heart Vasc 2019;24:100408. [PMID: 31453313 DOI: 10.1016/j.ijcha.2019.100408] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Linz D, Sanders P, Pitman B, Dobrev D, Lau DH. Atrial fibrillation in sub-Saharan Africa: The knowns and unknowns? Int J Cardiol Heart Vasc 2019;22:212-3. [PMID: 30963098 DOI: 10.1016/j.ijcha.2019.02.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
10 Qian Y, Zhang J, Li J, Weng Z. A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation. PLoS One 2021;16:e0259199. [PMID: 34762667 DOI: 10.1371/journal.pone.0259199] [Reference Citation Analysis]
11 Gawałko M, Kapłon-Cieślicka A, Hohl M, Dobrev D, Linz D. COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications. Int J Cardiol Heart Vasc 2020;30:100631. [PMID: 32904969 DOI: 10.1016/j.ijcha.2020.100631] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
12 Newman TV, Chen N, He M, Saba S, Hernandez I. Effectiveness and Safety of Restarting Oral Anticoagulation in Patients with Atrial Fibrillation after an Intracranial Hemorrhage: Analysis of Medicare Part D Claims Data from 2010-2016. Am J Cardiovasc Drugs 2020;20:471-9. [PMID: 31808136 DOI: 10.1007/s40256-019-00388-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Gawałko M, Jespersen T, Dobrev D, Linz D. The gut microbial-derived metabolite trimethylamine N-oxide: A missing link between lifestyle-components and atrial fibrillation? Int J Cardiol Heart Vasc 2020;29:100581. [PMID: 32885798 DOI: 10.1016/j.ijcha.2020.100581] [Reference Citation Analysis]
14 Pluymaekers NAHA, Hermans ANL, Middeldorp ME, Kadhim K, Crijns HJGM, Sanders P, Linz D. Gender differences and daily variation in atrial fibrillation risk factor profiles: Considerations for risk factor management. Int J Cardiol Heart Vasc 2019;25:100442. [PMID: 31890862 DOI: 10.1016/j.ijcha.2019.100442] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Fender AC, Dobrev D. Bound to bleed: How altered albumin binding may dictate warfarin treatment outcome. Int J Cardiol Heart Vasc 2019;22:214-5. [PMID: 30963099 DOI: 10.1016/j.ijcha.2019.02.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Hermans ANL, van der Velden RMJ, Gawalko M, Verhaert DVM, Desteghe L, Duncker D, Manninger M, Heidbuchel H, Pisters R, Hemels M, Pison L, Sohaib A, Sultan A, Steven D, Wijtvliet P, Tieleman R, Gupta D, Dobrev D, Svennberg E, Crijns HJGM, Pluymaekers NAHA, Hendriks JM, Linz D; TeleCheck-AF investigators. On-demand mobile health infrastructures to allow comprehensive remote atrial fibrillation and risk factor management through teleconsultation. Clin Cardiol 2020;43:1232-9. [PMID: 33030259 DOI: 10.1002/clc.23469] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
17 Sutanto H, Dobrev D, Heijman J. Genome-wide association studies of atrial fibrillation: Finding meaning in the life of risk loci. Int J Cardiol Heart Vasc 2019;24:100397. [PMID: 31334334 DOI: 10.1016/j.ijcha.2019.100397] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Wakili R, Riesinger L, Fender AC, Dobrev D. Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease? Int J Cardiol Heart Vasc 2019;23:100369. [PMID: 31111088 DOI: 10.1016/j.ijcha.2019.100369] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Linz D, Baumert M, Desteghe L, Kadhim K, Vernooy K, Kalman JM, Dobrev D, Arzt M, Sastry M, Crijns HJGM, Schotten U, Cowie MR, McEvoy RD, Heidbuchel H, Hendriks J, Sanders P, Lau DH. Nightly sleep apnea severity in patients with atrial fibrillation: Potential applications of long-term sleep apnea monitoring. Int J Cardiol Heart Vasc 2019;24:100424. [PMID: 31763438 DOI: 10.1016/j.ijcha.2019.100424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]